By Blair Childs, Senior Vice President, Public Affairs
Premier applauds the House Energy and Commerce Committee for advancing bipartisan legislation to lower costs and increase competition in the drug marketplace. The COVID-19 pandemic intensifies the need to reinvigorate this debate and enact solutions to make life-saving treatments more affordable to Americans.
A key component to achieve a healthier drug marketplace is closing loopholes that allow gaming of the regulatory approval process. The Fairness in Orphan Drug Exclusivity Act (H.R. 4712), will help ensure that the special approval pathway, exclusivity period and tax benefits that are afforded to orphan drugs are preserved for only drugs that are truly developed to treat rare diseases.